Heidelberg Pharma AG (LON:0QW5)

London flag London · Delayed Price · Currency is GBP · Price in EUR
3.010
-0.140 (-4.44%)
At close: Oct 10, 2025
-4.44%
Market Cap121.51M
Revenue (ttm)2.63M
Net Income (ttm)-22.67M
Shares Outn/a
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6
Average Volume114
Open3.010
Previous Close3.150
Day's Range3.010 - 3.010
52-Week Range2.110 - 5.420
Beta-0.28
RSI37.80
Earnings DateOct 10, 2025

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic cas... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 105
Stock Exchange London Stock Exchange
Ticker Symbol 0QW5
Full Company Profile

Financial Performance

In 2024, Heidelberg Pharma AG's revenue was 6.85 million, a decrease of -30.53% compared to the previous year's 9.86 million. Losses were -19.38 million, -4.74% less than in 2023.

Financial numbers in EUR Financial Statements

News

There is no news available yet.